Restless Legs Syndrome Treatment Market is segmented By Drug Class (Dopaminergic Agents (Ropinirole, Rotigotine), Opioids, Anticonvulsants(Gabapentin)....
Market Size in USD
CAGR5.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.7% |
Market Concentration | Medium |
Major Players | GlaxoSmithKline, Teva Pharmaceuticals, Boehringer Ingelheim, Pfizer Inc., UCB Pharma |
The restless legs syndrome treatment market is estimated to be valued at USD 2.5 Bn in 2024 and is expected to reach USD 2.64 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031. Growing awareness about the condition and its available treatment options is expected to drive the demand for restless legs syndrome drugs and devices.